STOCK TITAN
  1. Home
  2. News
  3. IKT

Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.

The presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website at www.inhibikcase.com, beginning Tuesday, March 9th, 2021 at 7:00 am ET. The webcast will be available for approximately 90 days following the event.

About Inhibikase (www.inhibikase.com)
Inhibikase (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase is currently escalating dose in its Phase I, randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-hc-wainwright--co-global-life-sciences-virtual-conference-301238073.html

SOURCE Inhibikase Therapeutics, Inc.

Stock IKT logo
Inhibikase Therapeutics, Inc.

NASDAQ:IKT

IKT Rankings

#5389 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IKT Latest News

May 15, 2024
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 15, 2024
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
May 9, 2024
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Apr 18, 2024
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Apr 3, 2024
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

IKT Stock Data

11.40M
5.57M
13.85%
9.58%
0.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ATLANTA

About IKT

inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.